Literature DB >> 12441073

Mechanism of neutralization of influenza virus infectivity by antibodies.

M Knossow1, M Gaudier, A Douglas, B Barrère, T Bizebard, C Barbey, B Gigant, J J Skehel.   

Abstract

We have determined the mechanism of neutralization of influenza virus infectivity by three antihemagglutinin monoclonal antibodies, the structures of which we have analyzed before as complexes with hemagglutinin. The antibodies differ in their sites of interaction with hemagglutinin and in their abilities to interfere in vitro with its two functions of receptor binding and membrane fusion. We demonstrate that despite these differences all three antibodies neutralize infectivity by preventing virus from binding to cells. Neutralization occurs at an average of one antibody bound per four hemagglutinins, a ratio sufficient to prevent the simultaneous receptor binding of hemagglutinins that is necessary to attach virus to cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441073     DOI: 10.1006/viro.2002.1625

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  69 in total

1.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

2.  Positive Selection in CD8+ T-Cell Epitopes of Influenza Virus Nucleoprotein Revealed by a Comparative Analysis of Human and Swine Viral Lineages.

Authors:  Heather M Machkovech; Trevor Bedford; Marc A Suchard; Jesse D Bloom
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

Review 3.  How innate immune mechanisms contribute to antibody-enhanced viral infections.

Authors:  Sukathida Ubol; Scott B Halstead
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

4.  Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines.

Authors:  Wilfred Ndifon; Ned S Wingreen; Simon A Levin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-13       Impact factor: 11.205

5.  Universal epitopes of influenza virus hemagglutinins?

Authors:  Taia T Wang; Peter Palese
Journal:  Nat Struct Mol Biol       Date:  2009-02-22       Impact factor: 15.369

6.  A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.

Authors:  Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

7.  A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.

Authors:  Takuya Yamamoto; Yuji Masuta; Masatoshi Momota; Masaru Kanekiyo; Tomohiro Kanuma; Shoukichi Takahama; Eiko Moriishi; Yasuhiro Yasutomi; Takashi Saito; Barney S Graham; Yoshimasa Takahashi; Ken J Ishii
Journal:  Int Immunol       Date:  2019-02-15       Impact factor: 4.823

Review 8.  Signaling by Antibodies: Recent Progress.

Authors:  Stylianos Bournazos; Taia T Wang; Rony Dahan; Jad Maamary; Jeffrey V Ravetch
Journal:  Annu Rev Immunol       Date:  2017-04-26       Impact factor: 28.527

9.  Structural Insight into a Human Neutralizing Antibody against Influenza Virus H7N9.

Authors:  Cong Chen; Liguo Liu; Yan Xiao; Sheng Cui; Jianmin Wang; Qi Jin
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

10.  The role of M cells of human nasopharyngeal lymphoid tissue in influenza virus sampling.

Authors:  Yoshinori Fujimura; Masaharu Takeda; Hidenori Ikai; Ken Haruma; Takeshi Akisada; Tamotsu Harada; Tatsuya Sakai; Masanobu Ohuchi
Journal:  Virchows Arch       Date:  2003-10-10       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.